What are the key numbers?
How does it work?
Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1, that signal fullness and help regulate blood sugar after meals.
What does the research say?
Published studies, strongest evidence first.
- Randomised trial
Phase 3 SURMOUNT-1 trial in 2,539 adults with obesity: weight fell 15.0% to 20.9% over 72 weeks depending on the group, versus 3.1% on placebo.
N Engl J Med, 2022 · PubMed
What should you know?
- There are randomised trials in people, the strongest kind of evidence.
- For research and education, not medical advice. Talk to a health professional before using any peptide.
Frequently asked questions
What is Tirzepatide?
A dual GIP and GLP-1 receptor agonist with large phase 3 trials in adults with obesity.
How strong is the evidence for Tirzepatide?
There are randomised trials in people, the strongest kind of evidence. This summary covers 1 published studies, each labelled by study type.
Is Tirzepatide registered with BPOM?
No. Tirzepatide from Continue is a research-grade compound, not a medicine, and is not registered with BPOM.
Where can I buy Tirzepatide with a COA in Indonesia?
Continue sells research-grade Tirzepatide with a COA for every batch, shipped cold across Indonesia.
